 The primary objective of this study is to evaluate the safety and tolerability of intravenously administered MEDI-545 compared with placebo, over a dose escalation range of 0.3-30 mgkg, in adult patients with SLE and who are receiving 20 mgday or less of prednisone orally or an equivalent dose of another oral corticosteroid. 